1.Heterogeneity of Adipose Tissue From a Single-cell Transcriptomics Perspective
Yong-Lang WANG ; Si-Si CHEN ; Qi-Long LI ; Yu GONG ; Xin-Yue DUAN ; Ye-Hui DUAN ; Qiu-Ping GUO ; Feng-Na LI
Progress in Biochemistry and Biophysics 2025;52(4):820-835
Adipose tissue is a critical energy reservoir in animals and humans, with multifaceted roles in endocrine regulation, immune response, and providing mechanical protection. Based on anatomical location and functional characteristics, adipose tissue can be categorized into distinct types, including white adipose tissue (WAT), brown adipose tissue (BAT), beige adipose tissue, and pink adipose tissue. Traditionally, adipose tissue research has centered on its morphological and functional properties as a whole. However, with the advent of single-cell transcriptomics, a new level of complexity in adipose tissue has been unveiled, showing that even under identical conditions, cells of the same type may exhibit significant variation in morphology, structure, function, and gene expression——phenomena collectively referred to as cellular heterogeneity. Single-cell transcriptomics, including techniques like single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq), enables in-depth analysis of the diversity and heterogeneity of adipocytes at the single-cell level. This high-resolution approach has not only deepened our understanding of adipocyte functionality but also facilitated the discovery of previously unidentified cell types and gene expression patterns that may play key roles in adipose tissue function. This review delves into the latest advances in the application of single-cell transcriptomics in elucidating the heterogeneity and diversity within adipose tissue, highlighting how these findings have redefined the understanding of cell subpopulations within different adipose depots. Moreover, the review explores how single-cell transcriptomic technologies have enabled the study of cellular communication pathways and differentiation trajectories among adipose cell subgroups. By mapping these interactions and differentiation processes, researchers gain insights into how distinct cellular subpopulations coordinate within adipose tissues, which is crucial for maintaining tissue homeostasis and function. Understanding these mechanisms is essential, as dysregulation in adipose cell interactions and differentiation underlies a range of metabolic disorders, including obesity and diabetes mellitus type 2. Furthermore, single-cell transcriptomics holds promising implications for identifying therapeutic targets; by pinpointing specific cell types and gene pathways involved in adipose tissue dysfunction, these technologies pave the way for developing targeted interventions aimed at modulating specific adipose subpopulations. In summary, this review provides a comprehensive analysis of the role of single-cell transcriptomic technologies in uncovering the heterogeneity and functional diversity of adipose tissues.
2.Integrative transcriptomic and epigenomic analysis identifies BCL6B as a novel regulator of human pluripotent stem cell to endothelial differentiation.
Yonglin ZHU ; Jinyang LIU ; Jia WANG ; Shuangyuan DING ; Hui QIU ; Xia CHEN ; Jianying GUO ; Peiliang WANG ; Xingwu ZHANG ; Fengzhi ZHANG ; Rujin HUANG ; Fuyu DUAN ; Lin WANG ; Jie NA
Protein & Cell 2025;16(11):985-990
3.Application Value of Vertebral CT Values in Fresh and Old Fractures Vertebral Bodies of Patients with Osteoporotic Vertebral Compression Fractures
Feng WANG ; Wei-sheng PENG ; Gui-liu CHEN ; Na DENG ; Xiao-bing HAN ; Hui-liang CAI ; Qiu-xiang CHEN
Progress in Modern Biomedicine 2025;25(19):3179-3185
Objective:To explore the value of using computed tomography(CT)values to distinguish fresh and old fractures vertebral bodies in osteoporotic vertebral compression fractures(OVCF).Methods:Retrospective analysis of clinical data of 101 OVCF patients in our hospital from September 2022 to September 2023.Kappa test for consistency between magnetic resonance imaging(MRI)and vertebral CT values in distinguished fresh or old OVCF.The difference of CT values between fresh,old fractures and adjacent normal vertebral bodies were compared.The diagnostic efficiency was analyed by receiver operating characteristic(ROC)curve.Results:There was a high consistency between vertebral CT values and MRI in the diagnosis of OVCF in fresh and old fractures(Kappa value=0.934).There was a difference in difference of CT values between adjacent normal vertebral bodies and fresh fractures vertebral bodies(P<0.05).There was a difference in difference of CT values of fresh fractures vertebral bodies and old fractures vertebral bodies(P<0.05).The ROC curve analysis results showed that,the combined measurement of CT values of fresh and old fractured vertebral bodies has an area under the curve(AUC)of 0.723,which was higher than alone measurement of the CT values of fresh fractured vertebral bodies and old fractured vertebral bodies of 0.536 and 0.610(Z=2.548,2.605,2.841,P<0.05).Conclusion:CT values of vertebral bodies show high consistency in distinguish fresh and old fractures of OVCF compared to MRI findings,and the diagnostic efficiency of combine detection is relatively high.
4.Diagnostic Value of Conventional CT Combined with Enhanced CT Scan in Bone Metastases
Feng WANG ; Gui-liu CHEN ; Wei-sheng PENG ; Na DENG ; Xiao-bing HAN ; Hui-liang CAI ; Qiu-xiang CHEN
Progress in Modern Biomedicine 2025;25(20):3337-3344
Objective:To explore the diagnostic value of conventional computed tomography(CT)combined with enhanced CT scan in bone metastases.Methods:This study was a retrospective observational study,84 suspected bone metastases patients admitted to our hospital from January 2022 to August 2024 were selected,All patients underwent conventional CT and enhanced CT scan and pathological examination,Using pathological examination results as the"gold standard"for diagnosis.The imaging manifestations of bone metastases using conventional CT combined with enhanced CT scan examination were observed;The detection rate and bone metastases types of conventional CT and enhanced CT scan were analyzed;The bone metastases location in different types of malignant tumors were analyzed;The detection results of bone metastases between conventional CT and enhanced CT scan were compared;the diagnostic efficacy of conventional CT and enhanced CT scan alone and in combination for bone metastases were analyzed by Receiver operating characteristic(ROC)curve.Results:The detection rate of osteogenic,osteolytic,cystic and mixed bone metastases by conventional CT combined with enhanced CT scan was supered to that of conventional CT and enhanced CT scan alone(P<0.05).Bone metastases from lung cancer,breast cancer and other tumors mainly occur in the spine,limbs and ribs,while esophageal cancer,gastric cancer,liver cancer,prostate cancer,thyroid cancer,renal cancer,and nasopharyngeal cancer had relatively fewer bone metastases.The positive detection cases of bone metastases used conventional CT combined with enhanced CT scan were supered to those used conventional CT and enhanced CT scan alone.The sensitivity,specificity and accuracy of conventional CT combined with enhanced CT scan for the diagnosis of bone metastases were 94.00%,94.11%and 94.04%,respectively,and the positive/negative predictive values were 95.91%and 91.42%,respectively.The sensitivity,specificity and accuracy of conventional CT scan were 84.00%,78.78%and 80.95%,respectively,and the positive/negative predictive values were 85.71%and 74.28%,respectively.The sensitivity,specificity and accuracy of enhanced CT were 89.79%,85.71%and 88.09%,respectively.and the positive and negative predictive values were 89.79%and 85.71%,respectively.The diagnostic efficacy of conventional CT combined with enhanced CT scan for bone metastases was significantly better than that of conventional CT and enhanced CT scan alone.Conclusions:Conventional CT combined with enhanced CT scan can significantly improve the diagnostic efficiency of bone metastases,and provide an important basis for clinical treatment.
5.Application Value of Vertebral CT Values in Fresh and Old Fractures Vertebral Bodies of Patients with Osteoporotic Vertebral Compression Fractures
Feng WANG ; Wei-sheng PENG ; Gui-liu CHEN ; Na DENG ; Xiao-bing HAN ; Hui-liang CAI ; Qiu-xiang CHEN
Progress in Modern Biomedicine 2025;25(19):3179-3185
Objective:To explore the value of using computed tomography(CT)values to distinguish fresh and old fractures vertebral bodies in osteoporotic vertebral compression fractures(OVCF).Methods:Retrospective analysis of clinical data of 101 OVCF patients in our hospital from September 2022 to September 2023.Kappa test for consistency between magnetic resonance imaging(MRI)and vertebral CT values in distinguished fresh or old OVCF.The difference of CT values between fresh,old fractures and adjacent normal vertebral bodies were compared.The diagnostic efficiency was analyed by receiver operating characteristic(ROC)curve.Results:There was a high consistency between vertebral CT values and MRI in the diagnosis of OVCF in fresh and old fractures(Kappa value=0.934).There was a difference in difference of CT values between adjacent normal vertebral bodies and fresh fractures vertebral bodies(P<0.05).There was a difference in difference of CT values of fresh fractures vertebral bodies and old fractures vertebral bodies(P<0.05).The ROC curve analysis results showed that,the combined measurement of CT values of fresh and old fractured vertebral bodies has an area under the curve(AUC)of 0.723,which was higher than alone measurement of the CT values of fresh fractured vertebral bodies and old fractured vertebral bodies of 0.536 and 0.610(Z=2.548,2.605,2.841,P<0.05).Conclusion:CT values of vertebral bodies show high consistency in distinguish fresh and old fractures of OVCF compared to MRI findings,and the diagnostic efficiency of combine detection is relatively high.
6.Diagnostic Value of Conventional CT Combined with Enhanced CT Scan in Bone Metastases
Feng WANG ; Gui-liu CHEN ; Wei-sheng PENG ; Na DENG ; Xiao-bing HAN ; Hui-liang CAI ; Qiu-xiang CHEN
Progress in Modern Biomedicine 2025;25(20):3337-3344
Objective:To explore the diagnostic value of conventional computed tomography(CT)combined with enhanced CT scan in bone metastases.Methods:This study was a retrospective observational study,84 suspected bone metastases patients admitted to our hospital from January 2022 to August 2024 were selected,All patients underwent conventional CT and enhanced CT scan and pathological examination,Using pathological examination results as the"gold standard"for diagnosis.The imaging manifestations of bone metastases using conventional CT combined with enhanced CT scan examination were observed;The detection rate and bone metastases types of conventional CT and enhanced CT scan were analyzed;The bone metastases location in different types of malignant tumors were analyzed;The detection results of bone metastases between conventional CT and enhanced CT scan were compared;the diagnostic efficacy of conventional CT and enhanced CT scan alone and in combination for bone metastases were analyzed by Receiver operating characteristic(ROC)curve.Results:The detection rate of osteogenic,osteolytic,cystic and mixed bone metastases by conventional CT combined with enhanced CT scan was supered to that of conventional CT and enhanced CT scan alone(P<0.05).Bone metastases from lung cancer,breast cancer and other tumors mainly occur in the spine,limbs and ribs,while esophageal cancer,gastric cancer,liver cancer,prostate cancer,thyroid cancer,renal cancer,and nasopharyngeal cancer had relatively fewer bone metastases.The positive detection cases of bone metastases used conventional CT combined with enhanced CT scan were supered to those used conventional CT and enhanced CT scan alone.The sensitivity,specificity and accuracy of conventional CT combined with enhanced CT scan for the diagnosis of bone metastases were 94.00%,94.11%and 94.04%,respectively,and the positive/negative predictive values were 95.91%and 91.42%,respectively.The sensitivity,specificity and accuracy of conventional CT scan were 84.00%,78.78%and 80.95%,respectively,and the positive/negative predictive values were 85.71%and 74.28%,respectively.The sensitivity,specificity and accuracy of enhanced CT were 89.79%,85.71%and 88.09%,respectively.and the positive and negative predictive values were 89.79%and 85.71%,respectively.The diagnostic efficacy of conventional CT combined with enhanced CT scan for bone metastases was significantly better than that of conventional CT and enhanced CT scan alone.Conclusions:Conventional CT combined with enhanced CT scan can significantly improve the diagnostic efficiency of bone metastases,and provide an important basis for clinical treatment.
7.Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study
Xiaoshuai ZHANG ; Bingcheng LIU ; Xin DU ; Yanli ZHANG ; Na XU ; Xiaoli LIU ; Weiming LI ; Hai LIN ; Rong LIANG ; Chunyan CHEN ; Jian HUANG ; Yunfan YANG ; Huanling ZHU ; Ling PAN ; Xiaodong WANG ; Guohui LI ; Zhuogang LIU ; Yanqing ZHANG ; Zhenfang LIU ; Jianda HU ; Chunshui LIU ; Fei LI ; Wei YANG ; Li MENG ; Yanqiu HAN ; Li'e LIN ; Zhenyu ZHAO ; Chuanqing TU ; Caifeng ZHENG ; Yanliang BAI ; Zeping ZHOU ; Suning CHEN ; Huiying QIU ; Lijie YANG ; Xiuli SUN ; Hui SUN ; Li ZHOU ; Zelin LIU ; Danyu WANG ; Jianxin GUO ; Liping PANG ; Qingshu ZENG ; Xiaohui SUO ; Weihua ZHANG ; Yuanjun ZHENG ; Qian JIANG
Chinese Journal of Hematology 2024;45(3):215-224
Objective:To retrospectively analyze the treatment status of tyrosine kinase inhibitors (TKI) in newly diagnosed patients with chronic myeloid leukemia (CML) in China.Methods:Data of chronic phase (CP) and accelerated phase (AP) CML patients diagnosed from January 2006 to December 2022 from 77 centers, ≥18 years old, and receiving initial imatinib, nilotinib, dasatinib or flumatinib-therapy within 6 months after diagnosis in China with complete data were retrospectively interrogated. The choice of initial TKI, current TKI medications, treatment switch and reasons, treatment responses and outcomes as well as the variables associated with them were analyzed.Results:6 893 patients in CP ( n=6 453, 93.6%) or AP ( n=440, 6.4%) receiving initial imatinib ( n=4 906, 71.2%), nilotinib ( n=1 157, 16.8%), dasatinib ( n=298, 4.3%) or flumatinib ( n=532, 7.2%) -therapy. With the median follow-up of 43 ( IQR 22-75) months, 1 581 (22.9%) patients switched TKI due to resistance ( n=1 055, 15.3%), intolerance ( n=248, 3.6%), pursuit of better efficacy ( n=168, 2.4%), economic or other reasons ( n=110, 1.6%). The frequency of switching TKI in AP patients was significantly-higher than that in CP patients (44.1% vs 21.5%, P<0.001), and more AP patients switched TKI due to resistance than CP patients (75.3% vs 66.1%, P=0.011). Multi-variable analyses showed that male, lower HGB concentration and ELTS intermediate/high-risk cohort were associated with lower cytogenetic and molecular responses rate and poor outcomes in CP patients; higher WBC count and initial the second-generation TKI treatment, the higher response rates; Ph + ACA at diagnosis, poor PFS. However, Sokal intermediate/high-risk cohort was only significantly-associated with lower CCyR and MMR rates and the poor PFS. Lower HGB concentration and larger spleen size were significantly-associated with the lower cytogenetic and molecular response rates in AP patients; initial the second-generation TKI treatment, the higher treatment response rates; lower PLT count, higher blasts and Ph + ACA, poorer TFS; Ph + ACA, poorer OS. Conclusion:At present, the vast majority of newly-diagnosed CML-CP or AP patients could benefit from TKI treatment in the long term with the good treatment responses and survival outcomes.
8.Antimicrobial resistance genes and molecular typing of carbapenem-resis-tant Citrobacter freundii
Yu-ling LIN ; Qing-qing CHEN ; Peng-peng PENG ; Hui-na QIU ; Li-ping HU ; Xiao-li YAN ; Jian-ming ZHANG
Chinese Journal of Infection Control 2024;23(12):1486-1491
Objective To analyze the detection rate,distribution characteristics,resistance mechanism,and mo-lecular typing of carbapenem-resistant Citrobacter freundii(CRCF),providing theoretical basis for clinical treat-ment and prevention.Methods Antimicrobial susceptibility testing results of CRCF isolated from Quanzhou First Hospital Affiliated to Fujian Medical University from 2020 to 2023 were analyzed.Resistance phenotypes of the strains were verified;resistance genes were amplified;strain homology was analyzed by multi-locus sequencing ty-ping(MLST).Whole genome sequencing analysis was performed on CF17 strains carrying both blaVIM-1,and blaNDM-1.Results A total of 119 strains of non-repetitive Citrobacter freundii were detected,27 strains were CRCF,accounting for 22.7%.CRCF was mainly isolated from departments of neurosurgery and urology,and the specimen type was mainly midstream urine.Strains were resistant to both carbapenems and cephalosporins,less resistant to amikacin,susceptible to both tigecycline and polymyxin,and with a resistance rate of>50%to other antimicrobial agents.22 CRCF strains were successfully recovered and all were positive for antimicrobial resistance phenotype and genes.17 strains(77.3%)carried single resistance genes,including 14 strains carrying blaNDM-1,2 strains carrying blaKPC-2,and 1 strain carrying blaNDM-5.5 strains(22.7%)carried dual antimicrobial resistance genes,including strains carrying both blaKPC-2 and blaNDM-1(n=3),strain carrying both blaNDM-1 and blaIMP(n=1),and strain carrying both blaVIM-1 and blaNDM-1(n=1).A total of 8 ST types were detected,with 8 and 6 strains being ST1 16 and ST532,respectively.CF17 was ST1 16,carrying blaVIM-1 and blaNDM-1 on different plasmids,namely IncA and IncX3,respectively.Conclusion CRCF strains are mostly multidrug-resistant,with the presence of blaNDM-1 be-ing the major resistance mechanism.Some strains also carry dual resistance genes,mainly ST116 and ST532.CF17 is currently the first isolated and reported Citrobacter freundii that carries both blaVIM-1 and blaNDM-1 resistance genes in China.
9.Expert consensus on ethical requirements for artificial intelligence (AI) processing medical data.
Cong LI ; Xiao-Yan ZHANG ; Yun-Hong WU ; Xiao-Lei YANG ; Hua-Rong YU ; Hong-Bo JIN ; Ying-Bo LI ; Zhao-Hui ZHU ; Rui LIU ; Na LIU ; Yi XIE ; Lin-Li LYU ; Xin-Hong ZHU ; Hong TANG ; Hong-Fang LI ; Hong-Li LI ; Xiang-Jun ZENG ; Zai-Xing CHEN ; Xiao-Fang FAN ; Yan WANG ; Zhi-Juan WU ; Zun-Qiu WU ; Ya-Qun GUAN ; Ming-Ming XUE ; Bin LUO ; Ai-Mei WANG ; Xin-Wang YANG ; Ying YING ; Xiu-Hong YANG ; Xin-Zhong HUANG ; Ming-Fei LANG ; Shi-Min CHEN ; Huan-Huan ZHANG ; Zhong ZHANG ; Wu HUANG ; Guo-Biao XU ; Jia-Qi LIU ; Tao SONG ; Jing XIAO ; Yun-Long XIA ; You-Fei GUAN ; Liang ZHU
Acta Physiologica Sinica 2024;76(6):937-942
As artificial intelligence technology rapidly advances, its deployment within the medical sector presents substantial ethical challenges. Consequently, it becomes crucial to create a standardized, transparent, and secure framework for processing medical data. This includes setting the ethical boundaries for medical artificial intelligence and safeguarding both patient rights and data integrity. This consensus governs every facet of medical data handling through artificial intelligence, encompassing data gathering, processing, storage, transmission, utilization, and sharing. Its purpose is to ensure the management of medical data adheres to ethical standards and legal requirements, while safeguarding patient privacy and data security. Concurrently, the principles of compliance with the law, patient privacy respect, patient interest protection, and safety and reliability are underscored. Key issues such as informed consent, data usage, intellectual property protection, conflict of interest, and benefit sharing are examined in depth. The enactment of this expert consensus is intended to foster the profound integration and sustainable advancement of artificial intelligence within the medical domain, while simultaneously ensuring that artificial intelligence adheres strictly to the relevant ethical norms and legal frameworks during the processing of medical data.
Artificial Intelligence/legislation & jurisprudence*
;
Humans
;
Consensus
;
Computer Security/standards*
;
Confidentiality/ethics*
;
Informed Consent/ethics*
10.Antimicrobial resistance genes and molecular typing of carbapenem-resis-tant Citrobacter freundii
Yu-ling LIN ; Qing-qing CHEN ; Peng-peng PENG ; Hui-na QIU ; Li-ping HU ; Xiao-li YAN ; Jian-ming ZHANG
Chinese Journal of Infection Control 2024;23(12):1486-1491
Objective To analyze the detection rate,distribution characteristics,resistance mechanism,and mo-lecular typing of carbapenem-resistant Citrobacter freundii(CRCF),providing theoretical basis for clinical treat-ment and prevention.Methods Antimicrobial susceptibility testing results of CRCF isolated from Quanzhou First Hospital Affiliated to Fujian Medical University from 2020 to 2023 were analyzed.Resistance phenotypes of the strains were verified;resistance genes were amplified;strain homology was analyzed by multi-locus sequencing ty-ping(MLST).Whole genome sequencing analysis was performed on CF17 strains carrying both blaVIM-1,and blaNDM-1.Results A total of 119 strains of non-repetitive Citrobacter freundii were detected,27 strains were CRCF,accounting for 22.7%.CRCF was mainly isolated from departments of neurosurgery and urology,and the specimen type was mainly midstream urine.Strains were resistant to both carbapenems and cephalosporins,less resistant to amikacin,susceptible to both tigecycline and polymyxin,and with a resistance rate of>50%to other antimicrobial agents.22 CRCF strains were successfully recovered and all were positive for antimicrobial resistance phenotype and genes.17 strains(77.3%)carried single resistance genes,including 14 strains carrying blaNDM-1,2 strains carrying blaKPC-2,and 1 strain carrying blaNDM-5.5 strains(22.7%)carried dual antimicrobial resistance genes,including strains carrying both blaKPC-2 and blaNDM-1(n=3),strain carrying both blaNDM-1 and blaIMP(n=1),and strain carrying both blaVIM-1 and blaNDM-1(n=1).A total of 8 ST types were detected,with 8 and 6 strains being ST1 16 and ST532,respectively.CF17 was ST1 16,carrying blaVIM-1 and blaNDM-1 on different plasmids,namely IncA and IncX3,respectively.Conclusion CRCF strains are mostly multidrug-resistant,with the presence of blaNDM-1 be-ing the major resistance mechanism.Some strains also carry dual resistance genes,mainly ST116 and ST532.CF17 is currently the first isolated and reported Citrobacter freundii that carries both blaVIM-1 and blaNDM-1 resistance genes in China.

Result Analysis
Print
Save
E-mail